Case Presentation
=================

Children with intellectual disability in the Molise (Italy) school district were enrolled in genetic screening for chromosomal defects and copy number variations (CNVs). This study was carried out following the recommendations of the Declaration of Helsinki and the Italian law for biomedical experimentation with written informed consent from all subjects. The protocol was approved and authorized by Italian National Health Service Azienda Sanitaria Regionale del Molise (ASREM) bio-ethical Committee with protocol no. 68 -- November 5th, 2015 under the denomination "Epidemiologia delle malattie genetiche rare associate a sindromi dismorfiche e disabilità psichica nella Regione Molise." All subjects or their legal guardians gave written informed consent under the Declaration of Helsinki and the approved protocol, including full consent to the publication of the case and related picture. Patients were carefully selected to undergo a preliminary cytogenetic screening followed by chromosome microarray analysis (CMA).

The patient was born from a 38-year old mother and a 40-year old father. He is the third son of non-consanguineous Caucasian parents and was born at 37 weeks of gestation by cesarean section. Birth weight was 2400 g (3rd centile), length 48 cm (21st centile) and head circumference 31.5 cm (3rd centile). The Apgar score was eight at 1 min and nine at 5 min.

The patient did not experience seizures, but his motor and language development was delayed. He started walking when he was 18 months old, and he pronounced the first words only around 3 years old. When he was 4 years old, the neuropsychological assessment showed developmental disorders of speech and language, hyperkinetic disorder, and global developmental delay.

At the age of 6 years, the patient was referred to a clinical geneticist for evaluation of developmental delay and dysmorphic features. His physical examination showed microcephaly (head circumference, 48.5 cm, 1st centile), hypertelorism, depressed nasal root, bulbous tip, winged scapula, and toe walking (**Figure [1A](#F1){ref-type="fig"}**). He was clumsy in movements. Weight was 23 kg (72nd centile) and height was 117 cm (63rd centile).

![**(A)** The patient and his facies showing mild dysmorphological features. **(B)** Patient brain MRI is showing slight enlargement of the occipital horns with normal morphology. **(C)** Positive and negative views of the patient GTC-banded chromosomes six at 400 bands resolution with the arrows pointing to the deleted region. **(D)** High-resolution chromosome microarray analysis (CMA) in the patient. Deviations of probe Log2 ratios from zero of the SNP probes on chromosome 6q26-q27 cytoband indicate the deleted region identified in the genomic profile of the patient.](fgene-08-00206-g001){#F1}

Infant neuropsychiatric evaluation revealed mild cognitive delay (IQ of 67 using WPPSI-III), speech delay and learning difficulties, and developmental coordination disorder (DCD) (dyspraxia). The EEG examination showed the presence of minor electrical abnormalities (potential 4-5 c/s, 30--50 μV) prevailing on the left posterior regions. MRI of the brain detected slight enlargement of the ventricular system mainly in occipital horns with normal morphology (**Figure [1B](#F1){ref-type="fig"}**). Cardiac examination with echocardiogram was normal as well-ophthalmological and audiological evaluation. Ultrasound of kidneys and urinary tract shows the absence of anomalies. His medical history also included surgery to remove a thyroglossal duct cyst and frequent episodes of wetting and encopresis.

Chromosomes were obtained from cultured peripheral lymphocytes using Synchroset kit (Euroclone, Milano, Italy). The conventional technique of G banding analysis was used. DNA was extracted from whole blood using kit QIAamp DNA Mini (Qiagen, Hilden, Germany). DNA concentration and purity were determined with a ND-1000 Spectrophotometer (NanoDrop Technologies, Berlin, Germany).

The CytoScan HD array contains more than 2.6 million markers for the copy number analysis. Of these markers, 1,950,000 are unique, non-polymorphic oligonucleotide probes, and 750,000 are SNP probes used for genotyping. The average marker spacing is one probe per 1.1 kb, with a mean spacing of one probe per 1.7 kb on non-gene backbones and one probe per 880 bp in intragenic regions. The CytoScanHD assay was performed according to the manufacturer's protocol, starting with 250 ng DNA. Briefly: total genomic DNA was digested with a restriction enzyme (NspI), ligated to an appropriate adapter for the enzyme, and subjected to PCR amplification using a single primer. After digestion, with DNase I, the PCR products were labeled with a biotinylated nucleotide analog, using terminal deoxynucleotidyl transferase and hybridized to the microarray. Hybridization was carried out in the Hybridization Oven 645 while subsequent washing and staining were performed using the Fluidics Station 450. The array was then scanned with the Scanner 3000 7G and both quality control step and copy number analysis were performed using the Chromosome Analysis Suite Software version 3.1. The clinical significance of each CNV detected was assessed by comparison with an internal database of 3,000 clinical samples and public database of CNVs (ISCA, ClinVar, DECIPHER, DGV). All nucleotide positions were based on the February 2009 human reference sequence, assembly GRCh37/hg19, produced by the Genome Reference Consortium.

Twenty metaphases of the patient and the parents were analyzed after GTG banding at 400 chromosome band resolution. Karyotype showed a small deletion in the terminal region of the long arm of chromosome 6 in all the analyzed metaphases. The karyotype of the child was 46, XY, del(6)(q26→qter) (**Figure [1C](#F1){ref-type="fig"}**). This rearrangement was not detected in the parents. To map deletion breakpoint more accurately high-resolution CMA was made.

Results of SNP array analysis of the patient displayed a copy number loss in chromosome bands 6q26-q27 of about 7,988 Mb ranging from nucleotide 162,931,432 to 170,919,482 (**Figure [1D](#F1){ref-type="fig"}**). In this interval there are 36 protein-coding genes: PARK2, PACRG, QKI, C6orf118, PDE10A, SDIM1, TFT, PRR18, SFT2D1, MPC1, RPS6KA2, RNASET2, FGFR10P, CCR6, GPR31, TCP10L2, UNC93A, TTLL2, TCP10, C6orf123, MLLT4, KIF25, FRMD1, DACT2, SMOC2, THBS2, WDR27, C6orf120, PHF10, TCTE3, ERMARD, DLL1, FAM120B, PSMB1, TBP, PDCD2 (according to DECIPHER v9.15 <https://decipher.sanger.ac.uk/>). The haploinsufficiency of some genes must be implicated in the clinical phenotype of this patient with the telomeric deletion of 6q26-q27.

According to the International System for Human Cytogenetic Nomenclature \[ISCN, 2016\], the molecular karyotype of the patient (showing both the minimum and maximum extent of the deletion) was defined as follows: arr\[GRCh37\] 6q26-q27(162,931,432-170,919,482)x1 dn. No other pathological CNVs were identified, excluding well-known benign CNVs variants.

The *PARK2* gene maps in 6q26 deletion breakpoint. Consequently, *PARK2* coding sequence (MIM number: 602544; NM_004562), exon/intron boundaries and flanking intronic regions, were analyzed by PCR and direct sequencing ([@B12]) using ABI BigDye Terminator Sequencing Kit v.3.3 (Applied Biosystems, Foster City, CA, United States) and an ABI 310 Genetic Analyzer (Applied Biosystems). Sequencing did not show any other mutation.

Background
==========

About 1/2000 patients affected by mental retardation with developmental delay shows terminal deletion of the long arm of chromosome 6 ([@B13]). This condition is a rare cytogenetic disorder characterized by extended variation in the size of the deleted region that can go from cytogenetically visible to small submicroscopic deletions, ranging from 0.4 to 12 Mb ([@B13]). Only molecular cytogenetic techniques as fluorescent *in situ* hybridization (FISH) and comparative genomic hybridization (CGH) can precisely recognize and define the smaller terminal deletions ([@B9]; [@B4]; [@B25]).

Patients with distal deletion of chromosome 6q show also variable phenotypic features with only a few common symptoms that include, besides intellectual disability and developmental delay ([@B3]; [@B28]; [@B16]), also hypotonic muscle, seizure ([@B8]; [@B28]), dysmorphic features with spinal cord and brain anomalies ([@B6]; [@B17]). Agenesis/hypoplasia of the corpus callosum ([@B25]), hydrocephalus ([@B14]) or non-specific ventricle enlargement, lissencephaly, pachygyria, polymicrogyria, neuronal migration abnormality with periventricular nodular heterotopia (PNH) ([@B5]), olfactory bulb aplasia and anosmia ([@B10]) are the most frequently described brain defects in these patients. Craniofacial anomalies ([@B11]) are also common, and they include hypertelorism with broad nasal bridge, midface hypoplasia with cleft palate, long philtrum, thin upper lip and ear anomalies. Also, heart defects ([@B17]), retinal abnormalities ([@B22]; [@B1]), vertebral column defects ([@B14]), joint laxity with elbow and knee anomalies, and attention deficit hyperactivity disorder (ADHD) are described in numerous patients.

Several authors have tried to correlate the distal deletion of chromosome 6q to a distinct clinical phenotype ([@B26]; [@B3]; [@B21]; [@B30]). Others have sought to identify the minimum deleted interval containing the critical genes responsible for the major clinical problems ([@B7]; [@B23]; [@B19]). However, it is still very problematic to identify clinically patients carrying such deletion and to correlate deleted genes with a clinical phenotype ([@B21]).

Discussion
==========

Here, we report the clinical and genomic characterization of a patient with an intellectual disability, delayed language developmental and dyspraxia and minor dysmorphic features due to a non-recurrent 6q26-qter deletion identified using high-resolution CMA in a screening of patients with non-syndromic intellectual disability. In this patient haplodeficiency of chromosome 6q subtelomeric region is the result of a *de novo* event and it is not due to familiar unbalanced translocation. The breakpoint is mapped in 6q26 where is located the common fragile site FRA6E (**Figure [1D](#F1){ref-type="fig"}**). It is well-known that FRA6E is a genomic hotspot that predisposes to chromosomal deletion and it is considered the third most mutation-prone fragile site of the human genome ([@B18]; [@B2]). In the center of this genomic site is located the PARK2 gene that is a huge gene implicated in the autosomal recessive early-onset type of Parkinson disease. The *PARK2* gene encodes the ubiquitin ligase Parkin that has high expression level in human neurons. We believe that *PARK2* haploinsufficiency may have a role in the etiology of intellectual disability of this patient since we can exclude mutations in the other *PARK2* allele. Micro-deletions or duplications and CNV in *PARK2* are found in patients with Autism Spectrum Disorder ([@B24]). In mouse, *Park2* knock out does not reproduce any sign of the Parkinson disease ([@B20]). Instead, Parkin null mouse and the *quaking* mutant mouse, who carries a 1,8 Mb deletion of mouse chromosome 17 including *Park2*, show mainly neurological and behavioral problems ([@B15]; [@B29]).

The patient displays a cytogenetically visible deletion of about 8 Mb in size that causes haploinsufficiency of other 36 proteins coding genes. RNASET2, CCR6, DACT2, SMOC2, DLL1, and TBP are other brain-specific genes located in the deletion interval. They are all excellent candidate genes to affect brain functions and to generate with Parkin the clinical spectrum of the 6qter syndrome. However, the patient shows a mild phenotype. He has microcephaly, minimal enlargement of the cerebral ventricular system mainly in occipital horns and minor electrical abnormalities prevailing on the left posterior regions of the brain. Cerebral malformations are absent as eye and heart anomalies.

As described in previous studies ([@B26]; [@B3]; [@B30]), the 6q distal deletions are characterized by highly variable clinical symptoms that do not depend on the extension of the chromosomal abnormality. This condition can also happen in other contiguous gene deletion syndromes because any CNV can also affect the expression level of genes situated nearby the deleted or duplicated region, modulating the clinical consequences of haploinsufficiency ([@B27]). This "position effect" can explain the complexity and heterogeneity of the phenotype associated with terminal 6q deletion ([@B27]).

[@B19] have reported a very similar 6q terminal deletion in a female newborn. She had a 7.6 Mb heterozygous deletion at 6q26-qter between nucleotides 162,784,565--170,899,992 which determined multiple organ anomalies (right-sided subependymal nodular gray matter heterotopia and agenesis of the corpus callosum, bicuspid aortic valve, imperforate anus with perineal fistula, segmentation anomalies of the sacrum, dextroconvex scoliosis of the lumbosacral spine and tethered spinal cord). None of these symptoms are present in this patient. However, both patients showed hypertelorism, broad nasal bridge, and global developmental delay. Correlation between the two patients indicates that terminal 6q deletions that are genotypically almost overlapping can be remarkably dissimilar in phenotype and clinical severity.

Concluding Remarks
==================

To our knowledge, this is the first case of association between terminal 6q deletion and DCD. However, there are several genes in 6q26-27 region. Studies may narrow down the DCD candidates in the near future.

Author Contributions
====================

MDC, SiG, RC, and GM were responsible for clinical data and sample collection. MDC, AS, EM, PP, and OP made DNA extraction, karyotype, and CMA. RF and StG Park2 sequencing. MDC, AA, MC, and SiG analyzed the data and wrote the manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by Regione Molise Research Projects "Obiettivi di carattere prioritario 2012" no. 17 -- "Un ambulatorio mobile itinerante per le malattie genetiche rare nei piccoli Comuni della Regione Molise" and no. 7 -- "Cariotipo Molecolare nella diagnosi di autismo, schizofrenia e ritardo mentale ed interventi per la diagnosi precoce delle demenze" to SiG.

The authors would also like to show our gratitude to the patient and his family for the participation to this study. They also thank Maria Grazia Mastromonaco for nursing assistance and Dr. Roberto Fratangelo for help to recruit patients for this project.

[^1]: Edited by: *Musharraf Jelani, King Abdulaziz University, Saudi Arabia*

[^2]: Reviewed by: *Changsoo Kang, Sungshin Women's University, South Korea; Naveed Wasif, University of Ulm, Germany*

[^3]: This article was submitted to Genetic Disorders, a section of the journal Frontiers in Genetics
